SAN DIEGO, Aug. 30 /PRNewswire/ -- More than 2.2 million school-age
children have life-threatening food allergies and that number is expected
to rise according to the Food Allergy & Anaphylaxis Network. For these
children, heading back-to-school can spell increased risks unless prepared.
"Parents of food allergic children have to take an extra step when
their children are in a school environment, but this is a topic that
everyone should be aware of. Even if their child doesn't have severe food
allergies, chances are one of their child's friends do," says leading New
York-based allergist and immunologist, Clifford Bassett, M.D.,
F.A.C.A.A.I., F.A.A.A.A.I., Assistant Clinical Professor of Medicine and
Otolaryngology, at SUNY -- Long Island College Hospital and Faculty of NYU
School of Medicine. Dr. Bassett offers this advice for parents and
caregivers of food allergic children:
Study-Up: Parents should check their state laws and school policies to
see if children are allowed to bring epinephrine auto-injectors, the
standard treatment for anaphylaxis or a severe reaction, to school as
there are some states and school districts that ban these life-saving
devices. The American Medical Association recently voted to lobby for a
national law to allow children to carry their epinephrine auto-injectors,
such as Verus Pharmaceuticals' Twinject(R), with them at all times, but
until the bill is signed, it's important for parents to know and
understand their local laws.
Have a Back-Up: Studies show that approximately one in three anaphylactic
reactions require a second dose of epinephrine within minutes of the first
dose. It's essential to keep a back-up dose of epinephrine on-hand.
Twinject(R) is the only Food and Drug Administration approved
auto-injector that contains two doses of epinephrine in a single,
easy-to-use compact and convenient device.
Know the Drill: A food allergic child can be their own best advocate from
kindergarten through college. Parents should role play with their child so
they are fully aware of what they are allergic to and can ask teachers,
cafeteria staff and friends appropriate questions. In addition, it's
important for children to know the symptoms of a severe allergic reaction,
such as shortness of breath and hives, and have key people to turn to,
including school nurses, teachers, coaches and friends, in an emergency.
Be a Label Detective: Learn how to interpret and "de-code" food labels for
hidden ingredients that may wreak havoc if a child has a food allergy.
Even one-fiftieth of a teaspoon of a suspect allergen can cause a
potentially life-threatening reaction in a severely food allergic child.
Cross-contamination of cooking surfaces, utensils and cookware can pose a
danger, especially if it's not communicated to cafeteria and restaurant
staff. Preparing a "food allergen ingredient card" for the chef and
kitchen staff to ensure a safe dining experience can help.
Create ICE Cards: Give children identification or In Case of Emergency
(ICE) cards that have personalized information that includes their
allergens, emergency contact info and what to do in an emergency. This
can easily be handed to immediate caregivers in an emergency situation.
Make Time To Meet: Parents and caregivers should schedule a pre-meeting
with school officials to educate them on their child's needs and talk to
their local allergist to stay up to-date on the latest in food allergy
management. Organizations like the Food Allergy & Anaphylaxis Network and
parenting support groups offer great resources and information.
For more information on anaphylaxis, treatments and free resources such
as a downloadable Chef's Alert Food Allergy Card, Twinject Emergency Action
Plan and training videos, visit http://www.twinject.com.
Twinject(R) auto-injector 0.3 and 0.15 mg (epinephrine injection, USP
1:1000) is indicated in the emergency treatment of severe allergic reaction
including anaphylaxis to stinging and biting insects, allergen
immunotherapy, foods, drugs, diagnostic testing substances, and other
allergens, as well as anaphylaxis to unknown substance or exercise-induced
anaphylaxis. Twinject is the only available product approved by the FDA
that contains two doses of epinephrine in a single, compact device. This is
an important feature, as published studies demonstrate that for
approximately one in three patients, more than one dose of epinephrine may
be required to properly address the allergic reaction, with the second dose
often needed within 10 minutes after the first dose. Furthermore, a recent
study demonstrated that only 16 percent of patients carry two single-dose
auto-injectors at all times. More information about anaphylaxis and
Twinject is available on Verus' Twinject website at
Verus Pharmaceuticals is dedicated to improving the lives of children
and those who care for them. Verus is building a portfolio of products for
the unmet medical needs of children through acquisitions and alliances,
with an initial focus on the treatment of asthma, allergies, and related
diseases and conditions. Verus is differentiated by its pediatric
orientation and its strong financial position and experienced management
team, which allows the company to capitalize on an extensive network to
build its product portfolio and pursue complementary transactions. The
company's rigorous, disciplined approach to strategic decision-making and
core competencies in development and commercialization is expected to
provide significant value to its partners. More information about Verus is
available on the company's corporate website at http://www.veruspharm.com.
Verus(TM) and Twinject(R) are trademarks of Verus Pharmaceuticals, Inc.
Verus Pharmaceuticals cautions you that statements included in this
press release that are not a description of historical facts may be
forward-looking statements. The inclusion of forward-looking statements
should not be regarded as a representation by Verus that any of its plans
will be achieved. Actual results may differ materially from those set forth
in this press release due to the risks and uncertainties inherent in Verus'
business including, without limitation, statements about: its ability to
identify appropriate acquisition, licensing, or co-development and/or
promotion candidates in the future or be able to take advantage of the
opportunities it identifies; difficulties or delays in developing,
obtaining regulatory approval, manufacturing and commercializing its
products; unexpected performance or side effects of its products that could
delay or prevent development or commercialization, or that could result in
recalls or product liability claims; the scope and validity of patent
protection for its products; competition from other pharmaceutical
companies; and its ability to obtain additional financing to support its
operations. All forward-looking statements are qualified in their entirety
by this cautionary statement and Verus undertakes no obligation to revise
or update this press release to reflect events or circumstances after the
Important Safety Information
Twinject is designed as an emergency supportive therapy only and is not
a replacement or substitute for immediate medical care.
Side effects of Twinject may include anxiety, apprehensiveness,
restlessness, weakness, tremor, dizziness, headache, sweating, irregular
heartbeat, nausea, vomiting, and/or breathing difficulty. Twinject should
be used with extreme caution in people who have heart disease. There are no
absolute contraindications to the use of epinephrine in a life threatening
Epinephrine auto-injectors have fixed amounts of epinephrine. If the
patient weighs less than 33 pounds (15 kilograms), please consult a
Amy Caterina Jennifer Fernandes
Verus Pharmaceuticals, Inc. CarryOn Communication
SOURCE Verus Pharmaceuticals